Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nε-carboxymethyl lysine (CML)
- Target
- CML
- Molecular classification
- Advanced Glycation End Product (AGE), Modified Amino Acid
01
Overview
Nε-carboxymethyl lysine (CML) is an advanced glycation end product (AGE) formed by the non-enzymatic glycation and oxidation of proteins, specifically lysine residues. It acts as a ligand for receptors such as RAGE and CD36, triggering cellular responses linked to inflammation, oxidative stress, and tissue damage, particularly in metabolic disorders like diabetes and cardiovascular disease. CML is used as a biomarker for AGE accumulation and is being explored as a therapeutic target.
- Other names
- N(6)-Carboxymethyl-L-lysineε-(Carboxymethyl)lysineN(6)-CarboxymethyllysineN(epsilon)-Carboxymethyllysine
02
Mechanism of action
Binding to RAGE activates NF-kB pathway, leading to increased expression of inflammatory cytokines. Binding to CD36 promotes foam cell formation.
03
Biological functions
Ligand for RAGE and CD36Pro-inflammatory mediatorAGE accumulation
04
Disease associations
Diabetes mellitusAtherosclerosisCoronary artery diseaseObesityAge-related tissue dysfunctionsPancreatic Cancer (potential)
05
Safety considerations
Pro-inflammatory effects via RAGE activationContributes to oxidative stress and tissue damage
06
Interacting drugs
Humanized monoclonal antibody against Nε-carboxymethyl lysine (experimental)
07
Biomarkers
AGE accumulationDiabetes mellitus progressionAtherosclerosis/coronary artery disease severityObesity-related inflammation/insulin resistance
Beyond the preview
Go deeper on Nε-carboxymethyl lysine (CML).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nε-carboxymethyl lysine (CML).